#United States #Denver #Stealth BioTherapeutics #Dry AMD #Bevemipretide

Stealth BioTherapeutics Presents Bevemipretide Eye Drops Data

Stealth BioTherapeutics, a biotechnology firm dedicated to developing novel therapies for mitochondrial dysfunction, has achieved a significant milestone by completing enrollment for its Phase 1 dose escalation clinical trial. This trial focuses on bevemipretide eye drops, an innovative treatment option aimed at combating dry age-related macular degeneration (AMD).

Scheduled for presentation at the prestigious Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting 2026, taking place from May 3-7 in Denver, Colorado, the trial data will provide a critical insight into the safety, tolerability, and pharmacokinetics of the drug. The preliminary findings from both the single ascending dose (SAD) and multiple ascending dose (MAD) cohorts are expected to significantly contribute to the further development of this ocular therapy.

David R. Lally, MD, a prominent figure in retinal research, emphasized the importance of early intervention in dry AMD, stating, "Vision loss in dry AMD results from continual and irreversible photoreceptor loss, making timely treatment essential for preserving vision. A noninvasive approach, such as an eye-drop therapy, could enhance patient adoption and adherence early in this disease's progression."

The completion of the bevemipretide Phase 1 trial marks a pivotal step for Stealth BioTherapeutics as it moves towards initiating clinical trials dedicated to treating severe ophthalmic conditions, including dry AMD. Reenie McCarthy, the company's representative, stated, "We are dedicated to the advancement of mitochondrial-targeted treatments that can significantly improve patient quality of life."

Key Aspects of the Phase 1 Trial

The Phase 1 trial of bevemipretide, a mitochondrial cardiolipin binder, has a structured design aimed at establishing an optimal dosage range for subsequent clinical studies. The trial currently includes healthy volunteers and is divided into two parts: Part A involves assessing safety and tolerability through single ascending doses administered to three cohorts, while Part B focuses on multiple ascending doses across various participant groups.

In these trials, participants receive topical bevemipretide eye drops at varying concentrations (1%, 2%, or 3%), randomly assigned to test either their trial eye or fellow eye. Following each cohort's completion, safety evaluations and pharmacokinetic samples will guide future dosing regimens.

Understanding Dry AMD and the Need for Innovative Treatments

Dry AMD stands as a leading cause of vision impairment among older adults in developed nations. With estimated figures surpassing 10 million individuals affected in the United States alone, it showcases symptoms such as distorted vision, reduced overall visual acuity, and blurred vision. Unfortunately, current pharmacological options approved by the FDA or EMA do not exist to combat dry AMD, underlining the pressing need for groundbreaking treatments like bevemipretide.

Mitochondrial dysfunction plays a key role in dry AMD progression, making the mitochondrial network an appealing target for therapeutic intervention to enhance retinal function and relieve the burden of this disease.

In conclusion, Stealth BioTherapeutics is turning the medical community's attention towards bevemipretide eye drops, which potentially herald a new era in the management of dry AMD. The forthcoming data presentation at ARVO 2026 could mark a significant breakthrough in treatment strategies, offering new hope to patients suffering from this devastating condition. Stay tuned as we wait for updates from Dr. Lally at the ASRS 2026 regarding the final trial results and follow up on the anticipated Phase 2 trial initiation later this year.